Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 16Neoplasm Metastasis 4Breast Neoplasms 2Triple Negative Breast Neoplasms 1Granulosa Cell Tumor 1

Interventions

Trastuzumab 625Paclitaxel 576Cyclophosphamide 555Docetaxel 484Capecitabine 401Letrozole 376Fulvestrant 326Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 184Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 138Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × orteronel × Clear all
NCT01990209 2022-06-30

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

SCRI Development Innovations, LLC

Phase 2 Completed
71 enrolled 23 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01808040 2019-11-18

A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer

University of Wisconsin, Madison

Phase 1 Completed
8 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡